BIO-Europe in the Press

European biopharma faces an existential moment: adapt to new global realities or risk losing its innovation leadership.

Over three days, more than 32,000 meetings were facilitated between biotechs, pharma, venture capital, and industry service providers, with participants from more than 60 countries taking full advantage of their time in the Austrian capital to renew existing contacts and forge new ones.

There will be no return to normal for the European biopharma sector which needs to turn increasing macro-pressures into opportunities and become leaner and more efficient, experts at BIO-Europe said this week.

BIO-Europe 2025 in Vienna will gather global biopharma leaders to explore investment, manufacturing, and rare disease innovation.